THERAPY DOSSIER · th-3cd44b99d454

KL4 surfactant (lucinactant), synthetic peptide-containing surfactant

Drug · KL4 surfactant (lucinactant, Surfaxin) is a synthetic peptide-containing surfactant mixture; components in ChEMBL include colfosceril palmitate (CHEMBL1200737) and palmitic acid but no single lucinactant molecule

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: KL4 surfactant (lucinactant, Surfaxin) is a synthetic peptide-containing surfactant mixture; components in ChEMBL include colfosceril palmitate (CHEMBL1200737) and palmitic acid but no single lucinactant molecule
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 5

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00004500 ↗PHASE3terminated

Bronchoalveolar Lavage With Lucinactant vs Standard Care for Meconium Aspiration Syndrome

Meconium Aspiration

Enrolment: 69 · Results not recorded

NCT04389671 ↗PHASE2completed

Safety/Tolerability of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury

COVID-19 · ARDS

Enrolment: 20 · Results not recorded

NCT00934362 ↗PHASE2completed

Aerosolized Lucinactant and Vehicle on Mucociliary Clearance for Cystic Fibrosis

Cystic Fibrosis

Enrolment: 16 · Results not recorded

NCT00215540 ↗PHASE2terminated

Safety/Efficacy of SURFAXIN (Lucinactant) in Very Low Birth Weight Infants at Risk for BPD

Respiratory Distress Syndrome, Newborn

Enrolment: 136 · Results not recorded

NCT00578734 ↗PHASE2completed

Lucinactant in Acute Hypoxemic Respiratory Failure in Children Up to Two Years

Acute Hypoxemic Respiratory Failure

Enrolment: 165 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28877030 ↗2017Mixed findings

Radiation Mitigating Properties of Intranasally Administered KLSurfactant in a Murine Model of Radiation-Induced Lung Damage.

MouseRadiationC57BL/6Femalen = 15-30 mice per group depending on the assessment time point…Intranasal instillation under light isoflurane anaesthesia, enabling intrapulmonary deliveryApproximately 120 mg/kg total phospholipid per dose, given…Beginning 24 hours after irradiation

Model: Single 13.5 Gy targeted thoracic X-irradiation delivered on the Small Animal Radiation Research Platform via a single anterior-posterior 225 kV beam

KL4 surfactant preserved arterial oxygen saturation at 2, 4 and 18 weeks whereas untreated and vehicle-treated irradiated mice desaturated, lowered BALF white cell counts at the early phase (45 plus or minus 4 versus 64 plus or minus 3 untreated, p=0.018) with undetectable neutrophils at 18 weeks,…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…